Exploratory biomarker insights to guide your decision-making from discovery to the clinic
Accelerate your progress with a translational biomarker strategy
Access collaborative support with fit-for-purpose assay development and validation
Translational biomarkers can play a critical role in helping you quickly assess biomarker feasibility to better understand how it can be utilized in a clinical environment. When it comes to analytical characterization, one size doesn’t fit all. You need a flexible approach that considers your phase of development and desired outcomes to provide the best support for the intended use of your data.
Exploratory biomarkers, while not guided by specific regulations, still utilize robust quality principles, expertise and process to deliver high-quality and reliable data. A trusted partner who has familiarity with CAP/ CLIA and GxP environments can streamline your transition and retain critical insights about your assay and goals.
Since 2009, the Translational Biomarker Solutions (TBS) team has been supporting assay development and validation needs in an exploratory – but, principled – environment. Expertise in cellular analysis and immunoassays can help you develop your strategy from concept to implementation to meet your critical goals for exploratory biomarkers.
- Custom-immunogenicity assays
- Low-sample volume with improved detection
- Microfluidics-based ELISA
- Kit-based immune assays
- Immunoassay autoanalyzers
- High-parameter immunophenotyping of blood, PBMC and tissues
- Immunotoxicology for cytokine release
- Cellular Immunology
- Cell-Based Assays (including ADCCs, CDCs, Proliferation, Apoptosis and viability, etc.)
From initial feasibility and development to advanced validation, testing and production, we deliver insights to drive your decision making. Our team provides unique solutions for historic (banked) samples, difficult matrix types, or complex assay development in a flexible environment that provides robust exploration to guide new paths forward in biomarker discovery. As your clinical biomarker needs evolve, the TBS team can help you transition seamlessly into a CAP/CLIA or GxP environment for qualification, method validation and implementation.
Comprehensive knowledge of assays spanning ultrasensitive and multiplexed, kit-based and custom-built, low-sample volume and cell-based, gives you an experienced partner with access to a toolbox of diverse platforms. Together, we can support your biomarker analysis and advance your discovery through the use of precision technology, such as:
- Quanterix Simoa.
- Meso Scale Discovery (MSD)
- ECLIA (Roche e601)
- Cytoflex（Beckman Coulter 6色）
- Miltenyi Automacs Pro
- Miltenyi Octo Dissociator
- BD Fortessa X-20 (18-Color)
- CTL ImmunoSpot
In parallel with Covance’s regulated lab work, the TBS team works under a set of standardized quality principles to ensure accuracy and quality for your exploratory objectives of the studies. This system is further verified by both internal and external QA audits, as well as proficiency testing, giving you confidence that the data produced meets the highest standard of quality.
Next, meet the team that will work with you to help solve your translational biomarker challenges.
Erica L. Troksa, PhD
Associate Director, Translational Biomarker Solutions
Dr. Erica L. Troksa drives overall scientific performance and quality delivery of on-time services for the Translational Biomarker Solutions team. She leverages her16-plus years of experience in生物分析免疫测定的发展，优化和执行。Troksa博士已领导多种平台新型免疫测定的开发与验证。
在2013年3月加入Covance之前，她曾担任EMD Millipore的野外科学家，培训研究科学家在多路复用免疫测定中的适当技术，flow cytometry, protein quantitation and other technical applications.Troksa博士赢得了伊利诺伊大学芝加哥伊利诺伊大学的埃克斯·勒纳奖。她是关于各种议题的几个同行评审日刊文章的作者或共同作者。
Principal Scientist and Senior Lab Manager, Translational Biomarker Solutions, Covance
Dr. Paul C. Trampont leads a team of scientists and technical staff responsible for developing cell-based assays to support drug development. He joined Covance in December 2014, bringing with him more than 20 years of professional experience in human immunology and oncology research. Before joining Covance, he served as Assistant Professor in the Department of Medicine, Division of Hematology and Oncology at the University of Virginia.
Bhaskarjyoti Sarmah, PhD
Senior Scientist and Manager, Translational Biomarker Solutions
Bhaskarjyoti Sarmah博士带领我们的科学家团队负责开发，验证和实施可溶性生物标志物免疫测定和生物测定。He draws on more than 10 years of experience working in biomarker and target discovery research across multiple therapeutic areas, including cardio-metabolic, renal, autoimmune/inflammatory diseases, and immuno-oncology.
Dr. Sarmah is the author or co-author of more than two dozen journal articles, posters and presentations. Before joining Covance in January 2017, he served as a Research Scientist in Biotechnology Discovery Research for Eli Lilly & Co.
Chris W. Stamatkin, PhD
Dr. Chris W. Stamatkin serves as staff scientist and lead for Immunoassay and Special Chemistry. He leads the team of scientists and technical staff responsible for developing cell-based assays to support drug development. He joined Covance in November 2017, with over 14 years of experience in laboratory research and drug development.
Immunoassay Lead, Translational Biomarker Solutions
Ms. Masterson leads the team of scientists responsible for developing biomarker immunoassays and also consults clients on assay platforms and detection modalities. She joined Covance in January 2014, and brings over 15 years of experience in laboratory research and development to the table.